Our data suggest that targeting serine uptake by blocking a main serine plasma membrane amino acid transporter together with a facilitator of amino acid transport (in this case an ion exchanger) or a mitochondrial serine transporter, confers therapeutic benefit in serine synthesis-deficient cancer cells. This evidence concerns the gene SLC38A7 and cancer.